Clinical Trial Search

Primary: Percentage of Participants With Late-stage HAT Whose Treatment Outcome Was a Success at Month 18 According to Adapted World Health Organization (WHO) Criteria — 95.2…

Primary: Occurrence of Any TEAEs — 195; 69 Participants

Primary: Percentage of Participants Whose Treatment Outcome at Month 18 is a Success — 93.1 percentage of participants

Primary: Percentage of Evaluable Patients With Stage 2 r-HAT Who Died by the End of Hospitalization, Considering Only Deaths Possibly Related to r-HAT or Fexinidazole — 0…

Primary: Probability of Relapse-free Survival — 79; 71 percentage probability

Primary: Part 1 - Percentage of Sero-reduction or Sero-conversion (Cured Subjects) — 32.9; 18.9 Percentage of subjects

Primary: Safety and Reactogenicity (SAEs and AEs) — 45; 53; 22; 37 Number of events

Primary: Global PCR (Conventional PCR and Real-time Quantitative PCR) Immediately After the End of Treatment. — 16; 20 Participants

Primary: Number of Participants With and Without Intestinal Parasitic Infection — 36; 84 Participants

Primary: Number of Participants With Solicited Adverse Events Following V920 Vaccination — 5; 1; 2; 1 Participants

Primary: Number of Participants With Local Adverse Events (AEs) — 0; 1; 1; 1 Participants

Primary: The Primary Safety Endpoint - Frequency of Complications of Therapy — 414 participants

Primary: Incidence of Clinical Malaria Per Patient Year — 0.04; 3.05; 1.36 episodes/patient year

Primary: Difference in the Urinary L:M Ratio Before and After the Intervention — -0.01; 0.02 Ratio of lactulose-to-mannitol (L:M) exc

Primary: Number of Participants That Discontinued Due to Adverse Experience, by Type of Adverse Experience — 12; 10; 3; 1 Participants

Primary: The Peak % of Baseline Eosinophil Count Measured During the First 7 Days Post-treatment. — 196; 165 percentage of baseline — p=0.68

Primary: Controlled Hypertension — 3; 315; 37; 1 Participants

Primary: Plasmodium Falciparum Peripheral Parasitemia — 8; 7 Participants

Primary: Titers of ZEBOV-specific IgG Antibodies — 1227; 25; 344.5 ELISA units per ml

Primary: Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction — 15.6; 10.0; 82.1; 86.7 Percentage of participants

Primary: Prophylactic Outcome Defined by the Subject Having no Positive Smears — 93; 90; 92; 6 participants

Primary: Incidence-density of Malaria Defined as the Number of Incident Episodes of Malaria Per Time at Risk. — 1.32; 2.25 Episodes/ Person-Yr at Risk — p=0.04

Primary: Tolerability and Safety of the Treatment. — 0; 0 participants

Primary: Severe Events — 3.3; 4.2; 4.2 Events per 100 participant-years — p=<=0.05

Primary: Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination — 0; 5; 0; 12 Participants

Primary: Cross-reactive Antigenemia — 12 Participants

Primary: Number of Subjects With Plasmodium Falciparum (P. Falciparum) Parasitaemia (PFP), by Study Center — 235; 153; 167; 141 Participants

Primary: Cure Rates of AQ-13 and Coartem for Uncomplicated Plasmodium Falciparum Malaria in Adult Malian Males. — 28; 31 Participants

Primary: Infection Rate — 5; 6; 3; 0 Participants

Primary: Feasibility as Measured by the Number of Total Scheduled Intervention Sessions (CHW Counseling Sessions, Doctor's Visits, Phone Calls) Attended — 589 Scheduled sessions